ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 249

Patients with Fibromyalgia May be Fearful of Developing Dementia Despite Lack of Concrete Evidence of Cognitive Decline

Robert S. Katz1 and Frank Leavitt2, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Rush University Medical Center, Chicago, IL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: fibromyalgia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Fibromyalgia and Other Clinical Pain Syndromes Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Core features of cognitive dysfunction in fibromyalgia are memory loss and disturbance in mental clarity. The present study examines if disturbance in mental clarity, a core feature of fibromyalgia, shapes the fear of falling prey to Alzheimer’s in rheumatic disease groups with and without fibromyalgia.

Methods:

The self administered form of the new ACR criteria for fibromyalgia along with the Mental Clutter Scale were administered to 246 consecutive patients at a single office site. Scores on the new ACR criteria of ≥ 12 formed the fibromyalgia group. Scores ≥ 4 defined disturbance in mental clarity. Risk of Alzheimer’s disease, as judged by the patient, was measured on a 0 to 100 chance scale.

Results:

Perception of risk substantially increased with sharp reductions in mental clarity often referred to as brain fog, with risk increasing from 18.7 ± 20.7 to 46.2 ± 20.6 p<0.01 in the fibromyalgia group, and from 22.0 ± 23.2 to 41.1 ± 25.3, p<0.01 in controls. The percentage of people who perceived high risk was significantly higher among fibromyalgia patients ( 40.6% vs. 19.3%, p<0.01 ). The age of risk perception was very similar in the two groups (fibromyalgia 47.4±9.9 vs. 49.6±9.8, p=.38).

Conclusion:

Fear among people with fibromyalgia that Alzheimer’s will strike them is often presumed to be due to the development of memory problems in their young years. This is the first known evidence of an association between perceived risk of Alzheimer’s disease in fibromyalgia and poor mental clarity, a core component of cognitive dysfunction in fibromyalgia.

At the average age of 47, the risk views of the fibromyalgia group will be a costly burden in the years to come. Yet, there is no evidence that the cognitive problems of fibromyalgia transition to Alzheimer’s later in life.

A better understanding of the cognitive problems of fibromyalgia among clinicians would be an important advance.


Disclosure: R. S. Katz, None; F. Leavitt, None.

To cite this abstract in AMA style:

Katz RS, Leavitt F. Patients with Fibromyalgia May be Fearful of Developing Dementia Despite Lack of Concrete Evidence of Cognitive Decline [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/patients-with-fibromyalgia-may-be-fearful-of-developing-dementia-despite-lack-of-concrete-evidence-of-cognitive-decline/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-with-fibromyalgia-may-be-fearful-of-developing-dementia-despite-lack-of-concrete-evidence-of-cognitive-decline/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology